ArticleClinical and experimental immunology2005
Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells.
Article in Clinical and experimental immunology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 2 syntheses or guidelines pooled it, 222 citations in OpenAlex.
- Pooled it
- Nutritional modulators of ulcerative colitis: clinical efficacies and mechanistic view.World journal of gastroenterology · 2013Pooled it
- Effect of probiotics on clinical and immune parameters in enthesitis-related arthritis category of juvenile idiopathic arthritis.Clinical and experimental immunology · 2016Trial
- Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study.Journal of gastroenterology · 2011Trial
- Lactobacilli Mitigate Gut Inflammation by Modulating T-Helper/T-Regulatory Cells and Suppressing Signaling Pathways in Food-Derived Models.Probiotics and antimicrobial proteins · 2026Review
- Combined Synbiotics and Omega-3 Polyunsaturated Fatty Acids Enhance Clinical and Histological Recovery in DSS-Induced Ulcerative Colitis: An Experimental Study in Rats.Diseases (Basel, Switzerland) · 2026Article
- Gerobiotics: Exploring the Potential and Limitations of Repurposing Probiotics in Addressing Aging Hallmarks and Chronic Diseases.Probiotics and antimicrobial proteins · 2026Review
- Overview of the immunomodulatory role of bacterial probiotic-derived peptidoglycan: from molecular insights to therapeutic application.Frontiers in microbiology · 2026Review
- Lactobacilli-Derived Microbe-Associated Molecular Patterns (MAMPs) in Host Immune Modulation.Biomolecules · 2025Review
- Prevention and treatment of antibiotics-associated adverse effects through the use of probiotics: A review.Journal of advanced research · 2025Review
- Impact of a 7-day short peptide diet on gut microbiota and metabolomics in septic mice.Frontiers in nutrition · 2025Article
- Cheese starter cultures attenuate inflammation in the in vitro Caco-2 model.AIMS microbiology · 2025Article
- Probiotics: A multifaceted approach to health promotion-from disease prevention to food enrichment and delivery systems.AIMS microbiology · 2025Review
- Pasteurized form of a potential probiotic lactobacillus brevis IBRC-M10790 exerts anti-inflammatory effects on inflammatory bowel disease in vitro.BMC complementary medicine and therapies · 2024Article
- Screening for Lactic Acid Bacterial Strains as Probiotics Exhibiting Anti-inflammatory and Antioxidative Characteristic Via Immune Modulation in HaCaT Cell.Probiotics and antimicrobial proteins · 2023Article
- Exploring the Benefits of Probiotics in Gut Inflammation and Diarrhea-From an Antioxidant Perspective.Antioxidants (Basel, Switzerland) · 2023Review
- The Effect ofmSystems · 2022Article
- Protective Effect of Levilactobacillus brevis Against Yersinia enterocolitica Infection in Mouse Model via Regulating MAPK and NF-κB Pathway.Probiotics and antimicrobial proteins · 2022Article
- Review
- Probiotic supplementation attenuates age-related sarcopenia via the gut-muscle axis in SAMP8 mice.Journal of cachexia, sarcopenia and muscle · 2022Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IL-6/STAT-3 signals play key roles in inflammatory bowel disease (IBD). It is known that Lactobacillus casei strain Shirota (LcS) improves inflammatory disorders. This study aimed to elucidate the effect of LcS on murine chronic IBD and to clarify the mechanism. We focused the inhibitory effect of LcS on the production of IL-6 in lipopolysaccharide (LPS)-stimulated large intestinal lamina propria mononuclear cells (LI-LPMC) isolated from mice with chronic colitis and in RAW264.7 cells in vitro. We also determined in vivo the effect of LcS on murine chronic IBD models induced with dextran sodium sulphate and SAMP1/Yit mice. Finally, we examined the cellular determinants of LcS for the down-regulation of IL-6 secretion by LI-LPMC, RAW264.7 cells and peripheral blood mononuclear cells (PBMC) derived from patients with ulcerative colitis (UC). LcS, but not other strains of Lactobacillus, inhibited the production of IL-6 in LPS-stimulated LI-LPMC and RAW264.7 cells, down-regulating the nuclear translocation of NF-kappaB. The LcS-diet-improved murine chronic colitis is associated with the reduction of IL-6 synthesis by LI-LPMC. LcS also improved chronic ileitis in SAMP1/Yit mice. The release of IL-6 in vitro in LPS-stimulated LI-LPMC, RAW 264.7 cells and UC-PBMC was inhibited by a polysaccharide-peptidoglycan complex (PSPG) derived from LcS. This probiotic-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines such as IL-6 and IFN-gamma production in LPMC. Therefore, LcS may be a useful probiotic for the treatment of human inflammatory bowel disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.